Price Chart

Executive Summary

Quince Therapeutics (QNCX) has completed a reverse merger with Orphai Therapeutics, acquiring the private biotech in exchange for 3,258,517 shares of common stock and 67,101.235 shares of newly created Series C Convertible Preferred Stock. Concurrently, the company raised $115M in a PIPE financing from investors purchasing Series C Preferred Stock and warrants. The combined entity will operate under Quince, with a new board and management team, and will focus on Orphai's pipeline. The transaction closed immediately upon signing, with a shareholder vote required later to authorize the conversion of the preferred stock and increase the common stock authorized share count.

Key Financial Metrics

Key Facts

• Quince Therapeutics acquired Orphai Therapeutics via a reverse merger, issuing 3,258,517 common shares and 67,101.235 Series C Convertible Preferred shares as consideration.
• Concurrent PIPE financing raised at least $115M from investors purchasing Series C Preferred Stock and warrants at $797.50 per preferred share.
• The Series C Preferred Stock is convertible into 1,000 common shares each, subject to shareholder approval of the Preferred Stock Conversion Proposal.
• The Exchange Ratio for the merger is 0.6935, meaning each Orphai share converts into a fraction of a Quince share.
• Post-merger, the Quince board will consist of five members, with four designated by Quince and one by Orphai.
• Existing Quince and Orphai insiders signed lock-up agreements restricting share sales for up to 12 months, with a 5% monthly release starting after 180 days.
• The merger is structured as a tax-free reorganization under Section 368(a) of the Code.
• Quince's authorized common stock is 250M shares; a charter amendment to increase to 800M shares is subject to shareholder vote.
• The company's market cap is approximately $19M, and analyst consensus is 0% bullish (5 Hold, 2 Sell, 2 Strong Sell).

Financial Impact

Quince issued 3,258,517 common shares and 67,101.235 Series C Preferred shares (convertible into ~67.1M common shares) to Orphai holders. The PIPE raised $115M at $797.50 per preferred share, with each preferred share convertible into 1,000 common shares (subject to shareholder approval). Total potential dilution from the merger and PIPE could exceed 80M common shares, compared to the pre-deal 16.3M shares outstanding.

Risk Factors

• Massive dilution from the merger consideration and PIPE financing, with potential for over 80M new common shares.
• Shareholder approval required for the Preferred Stock Conversion Proposal and charter amendment; failure could limit conversion and create uncertainty.
• Integration risk combining two clinical-stage biotechs with different pipelines and cultures.
• Orphai's pipeline is pre-revenue and carries inherent clinical and regulatory risk.
• Lock-up agreements expire starting at 180 days, creating a potential overhang of insider shares.
• Low analyst confidence (0% bullish) and small market cap ($19M) suggest limited institutional support.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

US Market Status